Furthermore, another clinical trial starts recruiting in Portland, USA, to determine the optimal dosage and clinical benefits of administering pemigatinib following standard induction chemotherapy in patients newly diagnosed with AML characterized by an FGFR1 translocation. The gene discussed is FGFR1; the disease is acute myeloid leukemia.